Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) ARPA-H-SN-25-131
Summary
AI-generated · Sep 28, 2025ARPA-H has announced an Innovative Solutions Opening for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program to pursue novel, in vivo, precision genetic therapies for hereditary rare diseases. An associated Proposers Day will be hosted to inform potential proposers and provide registration details.
Stay tuned to SAM.gov for updates on the ISO, and review the attached ARPA-H-SN-25-131 for Proposers Day details and registration information. Additional program information is available on the THRIVE program page.
This Special Notice (SN) is intended to alert the scientific community to a newly approved ARPA-H Program and notify potential proposers of an associated Proposers Day (PD). Under the cognizance of HSF, ARPA-H is publishing an Innovative Solutions Opening (ISO) for the Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program no later than September 25, 2025, please monitor SAM.gov for updates (ARPA-H-SOL-25-122). For additional PD details and registration information see the attached special notice (ARPA-H-SN-25-131). For more information about the THRIVE program visit: https://arpa-h.gov/explore-funding/programs/thrive
From Special Notice posted on Sep 25, 2025The purpose of this amendment is to: 1. Extend the registration deadline for lightning talks and sidebars to October 2, 2025 at 08:59AM ET. 2. Extend the available days/hours for lightning talks and sidebars. Lightning talks and sidebars slots will now be available on October 3. 2025. Slots for the October 3rd lightning talks and sidebars will be available between 11:00AM ET to 2:00PM ET. In addition, slots for the October 2nd sidebars will now be available between 11:00AM ET and 7:00PM ET. Please see the revised Special Notice document for additional details. ------------------------------------------------------------------------------------------------------------ This Special Notice (SN) is intended to alert the scientific community to a newly approved ARPA-H Program and notify potential proposers of an associated Proposers Day (PD). Under the cognizance of HSF, ARPA-H is publishing an Innovative Solutions Opening (ISO) for the Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program no later than September 25, 2025, please monitor SAM.gov for updates (ARPA-H-SOL-25-122). For additional PD details and registration information see the attached special notice (ARPA-H-SN-25-131). For more information about the THRIVE program visit: https://arpa-h.gov/explore-funding/programs/thrive
From Special Notice posted on Oct 01, 2025Notice history
2-
-
Special Notice LATEST Posted Oct 01, 2025View changes (2)
- Description: Description was updated
- Response Deadline: Sep 30, 2025 → Oct 02, 2025
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA